Table S7 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0
Table S6 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0
Table S3 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0
Table S5 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0
Table S1 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0